You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨歌禮制藥(1672.HK)高開逾9% 皮下注射PD-L1抗體ASC22美國臨牀試驗申請獲批
格隆匯 01-18 09:22
格隆匯1月18日丨歌禮制藥(1672.HK)高開逾9%,報5.85港元創近兩年新高,暫錄七連漲,區間漲幅超63%,最新總市值64億港元。歌禮制藥-B昨日發佈公吿,公司的 ASC22(恩沃利單抗)獲美國食品藥品監督管理局(FDA)批准開展臨牀試驗,並啟動全球開發計劃。ASC22是一款用於慢性乙型肝炎功能性治癒的同類第一皮下注射PD-L1抗體。ASC22用於乙肝功能性治癒的IIa期和IIb期臨牀研究入選2021年美國肝病研究協會年會“大會最佳摘要”。被列入“大會最佳摘要”是一項殊榮,表明AASLD評議委員會對歌禮在慢性乙型肝炎領域的研究給予了高度評價。至2021年11月8日,歌禮從蘇州康寧傑瑞獲得ASC22用於治療包括乙型肝炎在內的所有病毒性疾病的開發和商業化的全球獨家權益。ASC22在所有病毒性疾病領域的全球銷售收入均歸屬於歌禮。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account